Over 100 Sanofi employees participating in a stuffed animal donation event for vulnerable children in the Boston-area

Over 100 Sanofi employees participating in a stuffed animal donation event for vulnerable children in the Boston-area

Empowering Communities Through Science and Service

Sanofi employees are making a positive impact through volunteerism, charitable donations, and community partnerships. From supporting local families in need to inspiring the next generation of scientists, Sanofi is driving meaningful change and fostering a brighter future.

Are You Reflected in Clinical Trials?

Increasing diversity in clinical trials has no one solution. A 360° approach is needed from investing in clinical trial centers, partnering with community organizations, raising awareness to address disparities, and reaching people where they are. Learn more about Sanofi’s approach to reach a future where inclusivity is at the forefront of clinical trial design.

A Sanofi manufacturing line.

Sanofi Tackles 340B Abuse with Innovative Credit Model

The 340B Drug Pricing Program was intended to help hospitals and clinics that serve a disproportionate number of low-income and uninsured patients by providing them with significantly reduced prices on outpatient drugs. However, patients are not benefiting from those savings. Sanofi’s 340B Credit Model is an effort to bring this program back to its original intent.

Lew celebrates his grandson's high school graduation with his family.

A 9/11 Survivor’s Triumph Over Leukemia & GVHD

Lew Christie’s remarkable journey exemplifies the power of hope and the unwavering support of family. From surviving 9/11 to battling leukemia and GVHD, discover how these pillars gave him the strength to defy unimaginable odds.

Sanofi’s Hemophilia Treatment goes Beyond the Bleed

We’re working with the hemophilia community to advance conversations and develop better patient-centric hemophilia treatments and care solutions.

Latest News

December 3, 2024
ASH: New data underscore Sanofi's commitment to innovation in rare blood diseases and cancers
November 15, 2024
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
October 24, 2024
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

Explore More

Third Quarter 2024 Results

October 25, 2024

Third quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

Inclusion and Social Impact Report: Our 2023 Efforts

We are committed to fostering an inclusive workforce and sense of shared purpose.

A Million Conversations

People need healthcare systems – at all levels – to better reflect society. So we must listen to marginalized communities more and use those insights to help the healthcare industry, policymakers and governments to fix the causes of these trust gaps.

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

MAT-US-2014105-v8.0-01/2024